

30 August 2013

## TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12<sup>th</sup> of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation;<br>Pack size and type | Current<br>subsidy and<br>(price) | New subsidy<br>and price | Sole supply brand<br>(Supplier) | Date of<br>listing/subsidy<br>change for tender<br>winning brand | Date of reference<br>pricing of other<br>listed brands | Sole Subsidised<br>Supply date (and<br>delisting of other<br>listed brands) | Brand (Supplier)<br>affected by<br>reference pricing<br>and delisting |
|---------------|-------------------------------------|-----------------------------------|--------------------------|---------------------------------|--|--|---|---|
| Ceftriaxone   | inj 500 mg, 10 ml;<br>1 vial        | \$2.70                            | \$1.50                   | Ceftriaxone-AFT<br>(AFT)        | 1 January 2014   | 1 March 2014   | 1 June 2014   | Veracol<br>(Multichem)  |
| Ceftriaxone   | inj 1 g vial, 10ml;<br>5 vials      | \$10.49                           | \$5.22                   | Ceftriaxone-AFT<br>(AFT)        | 1 January 2014   | 1 March 2014   | 1 June 2014   | Aspen Ceftriaxone<br>(Aspen)  |

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed and pack size has changed

The decisions were as follows:

| Chemical name               | Presentation;<br>Pack size and type   | Current<br>subsidy<br>and price | New<br>subsidy<br>and price | Sole supply<br>brand<br>(Supplier) | Date of listing for<br>tender winning brand | Date of subsidy<br>change for other<br>pack size | Sole Subsidised<br>Supply date (and<br>delisting of other<br>pack size) | Brand<br>(Supplier); pack<br>size affected by<br>reference pricing<br>and delisting |
|-----------------------------|---------------------------------------|---------------------------------|-----------------------------|------------------------------------|---|--|---|---|
| Paroxetine<br>hydrochloride | Tab 20 mg;<br>90 tablets blister pack | \$2.38 per<br>30 tablets        | \$4.32 per<br>90 tablets    | Loxamine<br>(Mylan)                | 1 November 2013                             | 1 January 2014                                   | 1 April 2014  | Loxamine (Mylan);<br>30 tablets blister<br>pack                                     |

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

### 3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation;<br>Pack size and type | Current pack price         | New pack price           | Hospital Supply Brand (Supplier) | DV Limit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---------------|-------------------------------------|----------------------------|--------------------------|----------------------------------|----------|---|--|---------------------------------|
| Ceftriaxone   | inj 500 mg, 10 ml;<br>1 vial        | \$2.70                     | \$1.50                   | Ceftriaxone-AFT (AFT)            | 1%       | 1 January 2014  | 1 March 2014   | Veracol (Multichem)             |
| Ceftriaxone   | inj 1 g vial, 10ml;<br>5 vials      | \$10.49                    | \$5.22                   | Ceftriaxone-AFT (AFT)            | 1%       | 1 January 2014  | 1 March 2014   | Aspen Ceftriaxone (Aspen)       |
| Ceftriaxone   | inj 2 g vial, 10ml;<br>1 vial       | \$5.20                     | \$2.75                   | Ceftriaxone-AFT (AFT)            | 1%       | 1 January 2014  | 1 March 2014   | Veracol (Multichem)             |
| Iloprost      | inj 50 mcg, 0.5 ml;<br>1 ampoule    | \$925.00 per<br>5 ampoules | \$89.50 per<br>1 ampoule | Arrow - Iloprost (Actavis)       | 1%       | 1 February 2014                                       | 1 April 2014   | Ilomedin (Bayer)                |

### 4. Tenders awarded to listed pharmaceuticals where only the current brand is listed and pack size has changed.

The decisions were as follows:

| Chemical Name            | Presentation;<br>Pack size and type   | Current pack price       | New pack price           | Hospital Supply Brand (Supplier) | DV Limit | Date of listing and price change of other pack size | Hospital Supply Status date | Brand (Supplier); pack size affected by subsidy change and delisting |
|--------------------------|---------------------------------------|--------------------------|--------------------------|----------------------------------|----------|---|-----------------------------|--|
| Paroxetine hydrochloride | Tab 20 mg;<br>90 tablets blister pack | \$2.38 per<br>30 tablets | \$4.32 per<br>90 tablets | Loxamine (Mylan)                 | 1%       | 1 November 2013                                     | 1 January 2014              | Loxamine (Mylan);<br>30 tablets blister pack                         |

## Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2011/12 Invitation to Tender dated 1 November 2011 and 2012/13 Invitation to Tender, dated 31 October 2012:

### 2011/12 Invitation to tender

| Chemical Name        | Line Item                    | Chemical Name            | Line Item    |
|----------------------|------------------------------|--------------------------|--------------|
| Granisetron          | Tab 1 mg                     | Lignocaine hydrochloride | Inj 1%, 2 ml |
| Intra-Uterine Device | IUD- Short length (5-8cm)    | Lignocaine hydrochloride | Inj 2%, 2 ml |
| Intra-Uterine Device | IUD- Standard length (6-9cm) |                          |              |

### 2012/13 Invitation to tender

| Chemical Name   | Line Item                  | Chemical Name        | Line Item              |
|---|----------------------------|----------------------|------------------------|
| Ipratropium bromide*  | aqueous nasal spray, 0.03% | Sodium chloride*     | Inj 0.9%, 10 ml        |
| Rosuvastatin  | Tab 5 mg                   | Sodium chloride*     | Inj 0.9%, 20 ml        |
| Rosuvastatin  | Tab 10 mg                  | Water for injection* | Purified for inj 5 ml  |
| Rosuvastatin  | Tab 20 mg                  | Water for injection* | Purified for inj 10 ml |
| Rosuvastatin  | Tab 40 mg                  | Water for injection* | Purified for inj 20 ml |
| Sodium chloride*  | Inj 0.9%, 5 ml             |                      |                        |
| *We expect to include these products listed above in the final 2013/14 Invitation to Tender for both the community and DHB hospital market. |                            |                      |                        |

For products included in the 2011/12 Invitation to Tender or the 2012/13 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.